Denosumab Delays Skeletal-related Events in Multiple Myeloma

Denosumab was non-inferior to zoledronic acid in delaying the time to skeletal-related events in patients with newly diagnosed multiple myeloma.
Denosumab was non-inferior to zoledronic acid in delaying the time to skeletal-related events in patients with newly diagnosed multiple myeloma.

Denosumab (Xgeva) was non-inferior to zoledronic acid in delaying the time to skeletal-related events in patients with newly diagnosed multiple myeloma, according to a press release.1

To compare the efficacy of denosumab in delaying bone complications with that of zoledronic acid, the international, double-blind, phase 3 '482 study (ClinicalTrials.gov Identifier: NCT01345019) randomly assigned 1718 newly diagnosed patients with multiple myeloma to receive subcutaneous denosumab and intravenous placebo every 4 weeks, or intravenous zoledronic acid and subcutaneous placebo every 4 weeks.

Preliminary results showed no significant difference in the time to skeletal-related events between the 2 treatment arms (hazard ratio, 0.98; 95% CI, 0.85-1.14; P = .01). Median time to the first on-study skeletal-related event was 22.83 months with denosumab vs 23.98 months with zoledronic acid.

The study failed to demonstrate superiority with denosumab in delaying time to the first skeletal-related event and delaying time to the first-and-subsequent skeletal-related events.

RELATED: Bendamustine-triplet in Front-line Multiple Myeloma

Denosumab treatment appeared to reduce the risk of progression or death by 18% (hazard ratio, 0.82; 95% CI, 0.68-0.99; P = .036), but there was no significant difference in overall survival between the 2 groups. The most common adverse events in the denosumab arm were diarrhea and nausea.

Amgen plans to submit these new data to the U.S. Food and Drug Administration to support a potential update to the prescribing information of denosumab.

Reference

  1. Amgen presents new data from phase 3 Xgeva (denosumab) study in multiple myeloma patients at the 16th International Myeloma Workshop [news release]. Thousand Oaks, CA: Amgen; March 3, 2017. http://www.amgen.com/media/news-releases/2017/03/amgen-presents-new-data-from-phase-3-xgeva-denosumab-study-in-multiple-myeloma-patients-at-the-16th-international-myeloma-workshop/. Accessed March 6, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters